Alkermes

Yahoo Finance • 4 months ago

Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2

DUBLIN, Aug. 22, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-2 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with narcolepsy ty... Full story

Yahoo Finance • 4 months ago

We Ran A Stock Scan For Earnings Growth And Alkermes (NASDAQ:ALKS) Passed With Ease

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. But the reality is that when a company loses money each year, for long enough, it... Full story

Yahoo Finance • 8 months ago

Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1

DUBLIN, April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy... Full story

Yahoo Finance • 10 months ago

Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript

Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript February 15, 2024 Alkermes plc misses on earnings expectations. Reported EPS is $0.22 EPS, expectations were $0.46. Alkermes plc isn’t one of the 30 most popular stocks among hed... Full story

Yahoo Finance • last year

12 Best Growth Stocks to Buy According to Billionaire Ray Dalio’s Bridgewater Associates

In this piece, we will take a look at the 12 best growth stocks to buy according to billionaire Ray Dalio's Bridgewater Associates. If you want to see more stocks in this selection, then take a look at 5 Best Growth Stocks to Buy According... Full story

Yahoo Finance • last year

Alkermes to Participate in Two Upcoming Investor Conferences

DUBLIN, Nov. 21, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences. Piper Sandler 35th Annual Healthcare Conference Date/T... Full story

Yahoo Finance • last year

12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds

In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 Best Small-Cap Biotech Stocks with Massiv... Full story

Yahoo Finance • 2 years ago

Independent Proxy Advisory Firm ISS Recommends Alkermes Shareholders Vote Against Sarissa Employees' Election to Alkermes Board

Recognizes Alkermes' Value Enhancement Plan, Board Refreshment and Business Momentum Recommends Voting 'FOR' Shane Cooke and Richard Pops and All Unopposed Alkermes Nominees ISS' Flawed Profitability Analysis Disregards 2022 Janssen Roya... Full story

Yahoo Finance • 2 years ago

UPDATE 1-Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes

(Adds details about Denner's departure from Biogen and his replacement) By Svea Herbst-Bayliss NEW YORK, June 13 (Reuters) - Activist investor Sarissa Capital may have cleared a stumbling block in its push for board seats at Alkermes whe... Full story

Yahoo Finance • 2 years ago

Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes

By Svea Herbst-Bayliss NEW YORK (Reuters) - Activist investor Sarissa Capital may have cleared a stumbling block in its push for board seats at Alkermes when one of its candidates resigned from the board of a company that has a commercial... Full story

Yahoo Finance • 2 years ago

Alkermes plc Reports First Quarter 2023 Financial Results

—  First Quarter Revenues of $287.6 Million Reflect Strong Performance of Proprietary Product Portfolio — —  GAAP Loss per Share of $0.25 and Basic and Diluted Non-GAAP Earnings per Share of $0.01 — —  Planned Separation of Oncology Busi... Full story

Yahoo Finance • 2 years ago

Alkermes Recommits to Equality on Equal Pay Day 2023

NORTHAMPTON, MA / ACCESSWIRE / April 12, 2023 / Alkermes (NASDAQ:ALKS) As part of last month's observance of Equal Pay Day , Alkermes reaffirms our commitment to closing long-standing pay gaps between men and women. We are proud of our ef... Full story

Yahoo Finance • 2 years ago

Why Seattle Genetics, Alkermes Are Currently Outperforming Their Peers

Seattle Genetics and Alkermes beat fourth-quarter estimates Thursday, pushing Alkermes stock into a brief breakout as SGEN stock soared. Continue reading... Full story

Yahoo Finance • 2 years ago

Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 45% Undervaluation?

How far off is Alkermes plc (NASDAQ:ALKS) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to today's valu... Full story

Yahoo Finance • 2 years ago

Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma

— Designation Marks Entry Point into MHRA's Innovative Licensing and Access Pathway (ILAP) Program in the UK — DUBLIN, Jan. 17, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa (nemvaleukin), the comp... Full story

Yahoo Finance • 2 years ago

Alkermes Approach to Corporate Responsibility

NORTHAMPTON, MA / ACCESSWIRE / November 15, 2022 / OUR APPROACH TO CORPORATE RESPONSIBILITY Stakeholder Engagement We recognize that our stakeholders - including employees, healthcare providers, patients, caregivers, investors, policy ma... Full story

Yahoo Finance • 2 years ago

Investors in Alkermes (NASDAQ:ALKS) have unfortunately lost 52% over the last five years

Statistically speaking, long term investing is a profitable endeavour. But along the way some stocks are going to perform badly. To wit, the Alkermes plc (NASDAQ:ALKS) share price managed to fall 52% over five long years. That's not a lot... Full story

Yahoo Finance • 2 years ago

Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5

The top five biotech stocks today have several commonalities: strong ratings, promising charts and membership on the IBD Tech Leaders list.... Full story

Yahoo Finance • 2 years ago

Northrop Grumman Leads 5 Defensive Plays Near Buy Points

Northrop Grumman headlines five stocks that are near or just above buy points, with the mettle to withstand a recession.... Full story

Yahoo Finance • 3 years ago

Global Growth Stocks To Watch On IBD's Screen Of The Day Include Two Oil Stocks

IBD's Screen Of The Day features two oil stocks near buy points. Also, this biotech with excellent earnings made the list.... Full story